Clinical Trials - August 8, 2022
BioInvent enrolls first patient in Phase 1/2a trial
BioInvent International has announced treatment of the first patient in a Phase 1/2a trial of its second anti-FcyRIIB antibody BI-1607 in combination with trastuzumab in HER2+ solid tumors. The first-in-human Phase 1 trial is a dose escalation study of BI-1607 combined with trastuzumab in HER2+ advanced or metastatic solid tumors. The selected dose of BI-1607 […]
Clinical Trials - July 21, 2022
Mendus publishes preclinical data
Mendus has announced the publication of in vivo data demonstrating significant anti-tumor synergies between the company’s allogeneic dendritic cell-based immune primer program ilixadencel and immune checkpoint inhibition via CTLA-4 blockade in the peer-reviewed journal OncoImmunology. “These preclinical data underpin the rationale behind our immune primer in playing multiple roles in overcoming immunosuppression and rewiring the […]
Clinical Trials - July 12, 2022
Nordic Nanovector to discontinue the PARADIGME trial
Nordic Nanovector has provided an update on PARADIGME, its Phase 2b trial of Betalutin in 3rd-line relapsed and anti-CD20 refractory follicular lymphoma. Following a comprehensive review and independent data evaluation of PARADIGME and a subsequent request for regulatory agency interaction, the Board of Directors has taken the difficult decision to discontinue the study, states the […]
Clinical Trials - July 5, 2022
Pila Pharma initiates toxicological studies
Pila Pharma has announced that the preclinical toxicological three-month studies of the active substance XEN-D0501 has begun. Pila Pharma is, as previously announced, preparing a clinical phase 2b study of the drug candidate XEN-D0501 for type 2 diabetes. Previously, XEN-D0501 has been evaluated in both toxicological safety studies and in phase 1 and 2a clinical […]
Clinical Trials - July 4, 2022
Ultimovacs completes patient recruitment in Phase II trial
Ultimovacs has announced the completed recruitment of 154 patients in the INITIUM trial. INITIUM is Ultimovacs’ Phase II clinical trial of its universal cancer vaccine UV1 in combination with the checkpoint inhibitors ipilimumab and nivolumab in metastatic malignant melanoma. Consistent with INITIUM’s event-driven design, topline progression-free survival results will be disclosed after progression of cancer […]
Clinical Trials - June 29, 2022
FDA approves Targovax IND application
The US Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for the combination of TG01 and QS-21 STIMULON. The IND is a major milestone for the TG mutant RAS program, and represents the first time that a TG vaccine is authorized for clinical trials in the USA, states the company. […]
